Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3408 for the Treatment of Melanoma

Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year

Robert Meehan, M.D., appointed as Chief Medical Officer, bringing extensive clinical development expertise to advance the Company’s radiotherapeutic pipeline

Excerpt from the Press Release:

BOSTON and VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ — Alpha-9 Oncology, a clinical-stage radiotherapeutic company developing targeted cancer therapies, today announced the initiation of dosing in a Phase 1 study evaluating A9-3408, a novel Actinium-225-based radiotherapeutic targeting melanocortin 1 receptor (MC1R) for the treatment of patients with melanoma. The Phase 1 study is a multi-center, open-label trial designed to evaluate the safety, dosimetry, and dose escalation of A9-3408 in patients with MC1R-positive melanoma, who have progressed on standard-of-care therapies.

This milestone advances Alpha-9’s melanoma program, which first entered the clinic last year with A9-3202, a Gallium-68-based imaging agent used to assess MC1R expression and identify patients for the A9-3408 therapeutic study.

“Dosing the first patient with our MC1R radiotherapeutic marks an important milestone for the company and validates our internal R&D platform,” said Paul Blanchfield, Chief Executive Officer, Alpha-9 Oncology. “We are excited to have initiated trials for our first therapeutic program and look forward to advancing additional best-in-class assets into the clinic as we aim to bring novel, life-improving treatments to people living with cancer.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release